Gastroenterology
Volume 138, Issue 2 , Pages 447-462 , February 2010

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

  • Christoph Sarrazin

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Christoph Sarrazin, MD, J. W. Goethe-University Hospital, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. fax: +49 69 6301 83112
    • ,
  • Stefan Zeuzem

Received 12 October 2009 ,Accepted 12 November 2009.

References 

  1. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75–90
  2. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23–38
  3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401
  4. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–1104
  5. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–1109
  6. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science. 1998;282:103–107
  7. Herrmann E, Neumann AU, Schmidt JM, et al. Hepatitis C virus kinetics. Antivir Ther. 2000;5:85–90
  8. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000;81:1631–1648
  9. Rauch A, James I, Pfafferott K, et al. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology. 2009;50:1017–1029
  10. Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009;49:1069–1082
  11. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973
  12. Reesink HW, Zeuzem S, Weegink CJ. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006;131:997–1002
  13. Foster GR, Hezode C, Bronowicki JP, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J Hepatol. 2009;50(Suppl 1):S22
  14. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a prove of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol. 2009;50(Suppl 1):S6
  15. Herlihy KJ, Graham JP, Kumpf R, et al. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob Agents Chemother. 2008;52:3523–3531
  16. Cooper C, Lawitz EJ, Ghali P, et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol. 2009;51:39–46
  17. Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral acitivity of the nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with peg-IFN and ribavirin for 28 days. Hepatology. 2008;48(Suppl):1024A
  18. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology. 2009;49:1460–1468
  19. Rossignol JF, Kabil SM, El-Gohary Y, et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574–580
  20. Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology. 2009;136:856–862
  21. Bacon B, Shiffman M, Lim J, et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR. J Hepatol. 2009;50:S381
  22. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567
  23. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–1777
  24. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46:631–639
  25. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838
  26. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50:1709–1718
  27. Sarrazin C, Hong J, Lim S, et al. Incidence of virologic escape observed during ITMN-191 (R7227) monotherapy is genotype dependent, associated with a specific NS3 substitution, and suppressed upon combination with peginterferon alfa-2a/ribavirin. J Hepatol. 2009;50(Suppl 1):S350
  28. Kukolj G, Benhamou Y, Manns MP, et al. BI 201335, a potent HCV NS3 protease inhibitor in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J Hepatol. 2009;50(Suppl 1):S347
  29. Afdhal N, Godofsky E, Dienstag J, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology. 2004;40(Suppl 1):726A
  30. Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology. 2008;48:398–406
  31. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500mg BID for 28 days. J Hepatol. 2008;48(Suppl 2):29A
  32. Larrey D, Benhamou Y, Lohse AW, et al. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol. 2009;50(Suppl 1):S383–S384
  33. Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther. 2009;14:23–32
  34. Troke P, Lewis M, Simpson P, et al. Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. J Hepatol. 2009;50:S351
  35. Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment-naive patients chronically infected with HCV genotype 1. J Hepatol. 2009;50(Suppl 1):S382–S383
  36. Lawitz E, Rodriguez-Torres M, DeMicco M, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol. 2009;50(Suppl 1):S384
  37. Villano S, Howe A, Raible D, et al. Analysis of HCV NS5B genetic variants following monotherapy wth HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology. 2006;44(Suppl 1):607A–608A
  38. Kneteman NM, Howe AY, Gao T, et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology. 2009;49:745–752
  39. McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother. 2009;53:2129–2132
  40. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008;198:800–807
  41. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769–1778
  42. Kim AY, Timm J, Nolan BE, et al. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis. 2009;199:737–741
  43. Colson P, Brouk N, Lembo F, et al. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology. 2008;47:766–767
  44. Rodriguez-Frias F, Cubero M, Esteban JI, et al. Detection of clinically relevant minor HCV and HBV antiviral-resistant mutants in treatment-naive patients using ultra-deep pyrosequencing. J Hepatol. 2009;50:S130
  45. Le Pogam S, Seshaadri A, Kosaka A, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother. 2008;61:1205–1216
  46. Marquis M, Deterding K, Erhardt A, et al. Genotypic and phenotypic analysis of hepatitis C virus NS5B polymerase variants to BILB1941 inhibition. Hepatology. 2008;48(Suppl):1159A
  47. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69:477–503
  48. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174–S184
  49. Ozeki I. Safety and antiviral activity of monotherapy with MP-424 for 24 weeks in naive patients with chronic hepatitis c virus genotype 1b infection. J Hepatol. 2009;50:S350
  50. Hopkins S, Heuman D, Gavis E, et al. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J Hepatol. 2009;50:S36
  51. Coelmont L, Gallay P, Bobardt M, et al. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor debio 025. J Hepatol. 2009;50:S36
  52. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007;132:1270–1278
  53. Marcellin P, Forns X, Goeser T, et al. Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208. Hepatology. 2009;50(Suppl):395A
  54. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005;21:743–752
  55. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem. 2005;280:36784–36791
  56. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother. 2004;48:4784–4792
  57. Koev G, Dekhtyar T, Han L, et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res. 2007;73:78–83
  58. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007;46:640–648
  59. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  60. Schiff E, Poordard F, Jacobson I, et al. Boceprevir combination therapy in null responders: response dependent on interferon responsiveness. J Hepatol. 2008;48(Suppl 2):46A
  61. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus peginterferon alfa-2b/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. J Hepatol. 2009;50(Suppl 1):S4
  62. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology. 2008;48:385–397
  63. Olsen DB, Carroll SS, Handt L, et al. HCV antiviral activity and resistance analysis in chronically infected chimpanzees treated with NS3/4A protease and NS513 polymerase inhibitors. J Hepatol. 2007;46:S298
  64. Gane EJ, Roberts SK, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J Hepatol. 2009;50(Suppl 1):S380
  65. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods. 2008;153:156–162
  66. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004;279:17508–17514
  67. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 2008;77:177–185
  68. Qiu P, Sanfiorenzo V, Curry S, et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res. 2009;37:e74
  69. Qi X, Bae A, Liu S, et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 2009;81:166–173
  70. Ludmerer SW, Graham DJ, Patel M, et al. A transient cell-based phenotype assay for hepatitis C NS3/4A protease: application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV. J Virol Methods. 2008;151:301–307
  71. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186–189
  72. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004;127:1347–1355
  73. Reiser M, Hinrichsen H, Benhamou JP, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005;41:832–835
  74. Zhou Y, Bartels DJ, Hanzelka BL, et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2008;52:110–120
  75. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem. 2007;282:22619–22628
  76. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol. 2008;9:R16
  77. Forestier N, Susser S, Welker MW, et al. Long term follow-up of patients previously treated with telaprevir. Hepatology. 2008;48(Suppl):760A
  78. Shiffman ML, Berg T, Poordad F, et al. A study of telaprevir combined with peginterferon-alfa-2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa-2a and ribavirin treatment: interim analysis. Hepatology. 2008;48(Suppl):1135A–1136A
  79. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protase inhibitor, administered as monotherapy in hepatitis C genotype 1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alfa). Hepatology. 2005;42(Suppl 1):233A
  80. Susser S, Forestier N, Welker MW, et al. Detection of resistant variants in the hepatitis C virus NS3 protease gene by clonal sequencing at long-term follow-up in patients treated with boceprevir. J Hepatol. 2009;50:S7
  81. Forestier N, Larrey D, Guyader D, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose study. Hepatology. 2008;48(Suppl):1132A
  82. Manns MP, Reesink HW, Moreno C, et al. Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV infected patients. Hepatology. 2008;48(Suppl):1023A
  83. Manns MP, Bourliere M, Benhamou Y, et al. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype-1 infection given as monotherapy and in combination with peginterferon alfa 2a and ribavirin. Hepatology. 2008;48(Suppl):1133A
  84. Reesink H, Bergmann J, de Bruijne J, et al. Safety and antiviral activity of SCH900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J Hepatol. 2009;50(Suppl 1):S35
  85. Lawitz EJ, Sulkowski MS, Jacobson IM, et al. Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. Hepatology. 2008;48(Suppl):403A
  86. Pasquinelli C, Eley T, Villegas C, et al. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. Hepatology. 2009;50(Suppl):225
  87. Hotho M, deBruijne J, O'Farrell A, et al. Accelerated clinical trial design to assess the saftey, tolerability and anti-viral activity of PHX1766, a novel HCV NS4/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients. Hepatology. 2009;50(Suppl):1576
  88. Seiwert SD, Hong J, Lim SR, et al. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. J Hepatol. 2007;46(Suppl 1):244A
  89. Manns M, Reesink H, Moreno C, et al. OPERA-1 trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J Hepatol. 2009;50(Suppl 1):S7
  90. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008;52:4356–4369
  91. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology. 2007;46(Suppl):862–863A
  92. Rodriguez-Torres M, Lawitz E, Flach S, et al. Antiviral activity, pharmacokinetics, saftey, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection. Hepatology. 2009;50(Suppl):LB17
  93. Lalezari J, Asmuth D, Casiro A, et al. Antiviral activity, safety and pharamcokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology. 2009;50(Suppl):LB18
  94. Bavisotto L, Wang CC, Jacobson IM, et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology. 2007;46(Suppl 1):255A
  95. Brainard DM, Anderson MS, Petry A, et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-naive genotype 1a, 1b and 3 HCV-infected patients. Hepatology. 2009;50(Suppl):1568
  96. Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem. 2005;280:39260–39267
  97. Tomei L, Altamura S, Bartholomew L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol. 2003;77:13225–13231
  98. Hammond JL, Rosario MC, Wagner F, et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. Hepatology. 2008;48(Suppl):1024A–1025A
  99. Shi ST, Herlihy KJ, Graham JP, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother. 2009;53:2544–2552
  100. Cooper C, Larouche R, Bourgault B, et al. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals. J Hepatol. 2009;50:S342
  101. Lawitz E, Cooper C, Rodriguez-Torres M, et al. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype 1 infection. J Hepatol. 2009;50(Suppl 1):S37
  102. Nicolas O, Boivin I, Berneche-D'Amours A, et al. Genotypic and phenotypic analysis of HCV NS5B variants selected from patients treated with VCH-916. J Hepatol. 2009;50:S349
  103. Thompson PA, Patel R, Showalter RE, et al. In vitro studies demonostrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology. 2008;48(Suppl):1164A
  104. Howe AY, Cheng H, Johann S, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother. 2008;52:3327–3338
  105. Shih I, Vliegen I, Peng B, et al. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology. 2007;46(Suppl 1):859A
  106. Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naive, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology. 2009;50(Suppl):5A
  107. Koev G, Mondal R, Beyer J, et al. Characterization of resistance mutations selected in vitro by the non-nucleoside HCV polymerase inhibitors ABT-333 and ABT-072. J Hepatol. 2009;50:S346–S347
  108. Nettles R, Chien C, Chung E, et al. BMS-790052 is a first-in-class potent hepatitis C virus NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology. 2008;48(Suppl):1025A
  109. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005;435:374–379
  110. Chatterji U, Bobardt M, Selvarajah S, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem. 2009;284:16998–17005
  111. Mathy JE, Ma S, Compton T, et al. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008;52:3267–3275
  112. Coelmont L, Kaptein S, Paeshuyse J, et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother. 2009;53:967–976
  113. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008;47:817–826
  114. Hopkins S, Scorneaux B, Huang Z, et al. The genetic and biochemical basis for resistance to SCY-635. Hepatology. 2008;48(Suppl):1117A–1118A
  115. Lawitz E, Rouzier R, Nguyen T, et al. Safety and antiviral efficacy of 14 days of the cycophilin inhibitor NIM811 in combination with pegylated interferon alpha 2a in relapsed genotype 1 HCV infected patients. J Hepatol. 2009;50:S379
  116. Goto K, Watashi K, Inoue D, et al. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. 2009;100:1943–1950
  117. Kaul A, Stauffer S, Berger C, et al. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009;5:e1000546
  118. Korba BE, Elazar M, Lui P, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069–4071
  119. Shiffman M, Ahmed A, Jacobson I, et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis. J Hepatol. 2009;50:S385–S386
  120. Morishima C, Shuhart MC, Wang CC, et al. Silymarin inhibits in vitro T cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138:671–681
  121. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Hepatology. 2009;50(Suppl):226

 Conflicts of interest The authors disclose no conflicts.

 Funding The authors have been supported by a Deutsche Forschungsgemeinschaft grant (Klinische Forschergruppe KFO 129, SA 940/2-3).

PII: S0016-5085(09)02113-1

doi: 10.1053/j.gastro.2009.11.055

Gastroenterology
Volume 138, Issue 2 , Pages 447-462 , February 2010

Article Tools

* Image Usage & Resolution